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Escherichia coli, Klebsiella pneumoniae, and 
Enterobacter spp. are a major cause of infections in 
hospitalised patients. The aim of our study was to 
evaluate rates and trends of resistance to third-gener-
ation cephalosporins and fluoroquinolones in infected 
patients, the trends in use for these antimicrobials, 
and to assess the potential correlation between both 
trends. The database of national point prevalence 
study series of infections and antimicrobial use among 
patients hospitalised in Spain over the period from 
1999 to 2010 was analysed. On average 265 hospitals 
and 60,000 patients were surveyed per year yield-
ing a total of 19,801 E. coli, 3,004 K. pneumoniae and 
3,205 Enterobacter isolates. During the twelve years 
period, we observed significant increases for the 
use of fluoroquinolones (5.8%–10.2%, p<0.001), but 
not for third-generation cephalosporins (6.4%–5.9%, 
p=NS). Resistance to third-generation cephalosporins 
increased significantly for E.  coli (5%–15%, p<0.01) 
and for K.  pneumoniae  infections (4%–21%, p<0.01) 
but not for Enterobacter spp. (24%). Resistance to fluo-
roquinolones increased significantly for E.  coli (16%–
30%, p<0.01), for K.  pneumoniae (5%–22%, p<0.01), 
and for Enterobacter spp. (6%–15%, p<0.01). We found 
strong correlations between the rate of fluoroqui-
nolone use and the resistance to fluoroquinolones, 
third-generation cephalosporins, or co-resistance to 
both, for E.  coli (R=0.97, p<0.01, R=0.94, p<0.01, and 
R=0.96, p<0.01, respectively), and for K.  pneumoniae 
(R=0.92, p<0.01, R=0.91, p<0.01, and R=0.92, p<0.01, 
respectively). No correlation could be found between 
the use of third-generation cephalosporins and resist-
ance to any of the latter antimicrobials. No significant 
correlations could be found for Enterobacter spp.. 
Knowledge of the trends in antimicrobial resistance 
and use of antimicrobials in the hospitalised popula-
tion at the national level can help to develop preven-
tion strategies.
Introduction 
Enterobacteriaceae are a major cause of infections in 
hospitalised patients [1]. Among them, the most fre-
quent are Escherichia coli, Klebsiella pneumoniae, 
and Enterobacter spp. [2], with E.  coli being the most 
frequent cause of bacteraemia, and community and 
hospital-acquired urinary tract infections (UTI) [3]. 
Bacteria of the genus Klebsiella frequently colonise the 
gastrointestinal tract, but can also be associated with 
opportunistic infections, including those of the urinary 
and respiratory tract. These organisms can spread rap-
idly among patients, mostly via the hands of hospital 
personnel, causing nosocomial outbreaks [4]. Within 
the Klebsiella genus, K.  pneumoniae is the second 
leading cause of gram-negative bloodstream infections 
after E. coli [3]. In the family of the Enterobacteriaceae, 
Enterobacter spp. are also frequent pathogens that can 
cause opportunistic infections in hospitalised patients, 
especially in those who are immunocompromised or 
have mechanical ventilation support [1].
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Fluoroquinolones and third-generation cephalosporins 
are classes of antibiotics frequently used for the treat-
ment of infections caused by all of these organisms [1]. 
As a result of their extensive use, a continuous decline 
of the therapeutic effectiveness of these antimicrobial 
agents has been observed. This was predicted and 
seems unavoidable [5].
The aim of our study was to evaluate the rates and 
trends of resistance to different antimicrobials, par-
ticularly fluoroquinolones and third-generation cepha-
losporins, in the main Enterobacteriaceae causing 
nosocomial and community-acquired infections in hos-
pitalised patients in Spain over a twelve year period 
(1999–2010), the trends in use of these antimicrobials 
within this period, and to assess a potential correlation 
between both trends.
Methods 
Since 1990, point prevalence study series of noso-
comial and community-acquired infections among 
patients hospitalised in acute care facilities have been 
conducted in Spain (Estudio de prevalencia de las 
infecciones nosocomiales en los hospitales españoles 
– EPINE study). Each year in May, acute care hos-
pitals in Spain are requested to voluntarily join the 
EPINE prevalence study. In some of the regions it is 
compulsory to conduct this study or any other preva-
lence audit. Participating hospitals fill a standardised 
questionnaire on each hospitalised patient as well as 
provide overall data on the hospital and the hospital’s 
wards. Every participating hospital designates a hos-
pital contact point as the person responsible for the 
survey at the hospital level and for communicating with 
the EPINE executive board.  
Infection diagnosis relied on Centers for Disease 
Control and Prevention (CDC) case-definitions for 
nosocomial infections [6]. Infections that met the CDC 
criteria but developed outside of the hospital or in the 
first 48 hours upon admission were categorised as 
community-acquired infections. In addition to informa-
tion on the source of the infection and the associated 
microorganisms, the patient forms collected from the 
hospitals included demographic data (age and sex), 
use of antimicrobial (as the number of patients receiv-
ing any antibiotic per 100 patients on the day of the 
survey), type of ward (general medical as opposed to a 
surgical, intensive care, paediatric or obstetric ward), 
and size of the hospital as measured by the number 
of beds (small: less than 200 beds, medium: 200–500 
beds, large: more than 500 beds). The survey was per-
formed by trained doctors, nurses and, in some hospi-
tals, medical students. All the forms were revised for 
inconsistency and a percentage of them (10–15%) were 
validated by the hospital contact point after revising 
medical records. Hospital validated forms were sent to 
an independent central analysis unit. A hospital report 
was sent back to every participating hospital to avoid 
possible disagreements before final integration of the 
collected results in a centralised database. We focused 
our analysis on resistance and antimicrobial use during 
the period from 1999 to 2010. 
Standard microbiological procedures were used by 
different institutions in their corresponding micro-
biology departments or laboratories that followed 
accreditation or certification procedures following 
local health authorities’ requirements. Interpretive 
criteria (breakpoints) for susceptible, intermediate 
and resistant categories were those included in the 
Clinical and Laboratory Standards Institute guidelines 
[7,8]. Resistant isolates included both intermediate 
and resistant isolates as reported by the microbiologi-
cal laboratory to the clinician. As not all the micro-
biology laboratories tested the same antibiotics in 
susceptibility testing, resistance rates were expressed 
as percentage of isolates that were resistant to fluo-
roquinolones (ciprofloxacin or levofloxacin) or third-
generation cephalosporins (ceftriaxone, cefotaxime or 
ceftazidime). No further characterisation of resistance 
mechanisms was recorded. Comparisons of character-
istics of infections were made by Pearson’s chi-square 
test. To determine significant trends over time of 
resistance rates and proportion of use, the Cochran-
Armitage test was used. For correlation of antimicro-
bial use and the annual prevalence rates, Spearman 
correlation coefficient and regression coefficient were 
calculated. A p value <0.05 was considered significant. 
All calculations were performed with Stata/SE 9.0 sta-
tistical software.
Results
Between 1999 and 2010 an average of 265 hospitals 
per year (increasing from 233 in 1999 to 287 in 2010) 
participated in the EPINE survey yielding a sample of 
almost 60,000 hospitalised patients per year. Of a 
total of 303 hospitals participating in the survey at 
any given year, 230 took part in the entire twelve-year 
series.
During the period from 1999 to 2010 a total of 19,801 
E.  coli, 3,004 K.  pneumoniae and 3,205 Enterobacter 
spp. isolates — including mainly E.  cloacae (72%) and 
E.  aerogenes (18%) species — causing nosocomial or 
community-acquired infections were recorded. The 
main characteristics of the corresponding infections 
for the period from 1999 to 2010 are displayed in Table 
1. More than half of the infections occurred in patients 
aged over 65 years. E. coli infections were slightly more 
frequent in females, in contrast with K. pneumoniae or 
Enterobacter spp. infections (p values<0.001). Overall, 
about three quarters of infections were identified in 
patients hospitalised in medical or surgical wards but 
for Enterobacter spp. infections the ratio medical/sur-
gical ward was inversely (0.64) related to the ratio for 
E.  coli or K.  pneumoniae (1.42 and 1.56, respectively). 
Intensive care unit (ICU) infections accounted for 14% 
and 17% of K. pneumoniae and Enterobacter spp. infec-
tions respectively, in contrast to only 7% of E.  coli 
infections. UTI was the most common localisation of 
infection for E.  coli and for K.  pneumoniae but not for 
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Enterobacter spp.. Bloodstream infection represented 
11.3%, 11.4% and 14% of the infection locations for 
each microorganism.
Escherichia coli infections
The characteristics of patients and hospitals where 
third-generation cephalosoporin resistance was found 
are shown in Table 2. Rates of resistance by type of 
ward ranged from 4.4% in gynecology and obstetrics 
to 13.3% in ICU patients, and by localisation of infection 
from 8.7% for UTI to 14.7% for respiratory infections. 
Information on fluoroquinolone resistance can also be 
found in table 2. Fluoroquinolone resistant E. coli infec-
tions were detected in patients from both sexes and 
all age groups seemed to be affected (although there 
appeared to be lower rates in age groups younger than 
16 years old). Fluoroquinolone resistant E. coli could be 
community-acquired, but was more frequent in noso-
comial infections, and in the largest hospitals. There 
were differences in the rates of fluoroquinolone resist-
ance related to the type of ward and site of infection 
ranging from 5.4% in paediatric to 31.4% in medical 
wards and 32.6% in other hospital wards, and from 
22.9% for surgical site wounds to 30.9% for respiratory 
tract infections (Table 2). 
Klebsiella pneumoniae infections
Nosocomial infections as well as hospital size and type 
of ward, were associated with third-generation cepha-
losporin resistance. No difference for fluoroquinolone 
resistance was found by sex of the patients. High rates 
of fluoroquinolone resistant K. pneumoniae were found 
Table 1
Main characteristics of patients infected by Escherichia coli, Klebsiella pneumoniae, or Enterobacter species in Spanish 
hospitals, Spain, 1999–2010 (n=672,362)
 
 
Escherichia coli Klebsiella pneumoniae Enterobacter spp. (Enterobacter cloacae)a
n % n % n %
Sex
Male 9,004 46.2 1,635 55.3 2,048 (1,432) 64.8 (62.9)
Female 10,498 53.8 1,321 44.5 1,114 (843) 35.2 (37.1)
Age (in years)
≤1 1,165 5.9 178 5.9 178 (137) 5.6 (6.0)
1–15 567 2.9 40 1.3 48 (38) 1.5 (1.7)
16–45 2,116 10.7 399 13.3 470 (322) 14.7 (14.0)
46–65 3,963 20 724 24.2 802 (570) 25.1 (24.8)
>65 11,964 60.5 1,654 55.2 1,696 (1,233) 53.1 (53.6)
Localisation of infection
Urinary tract 10,051 51.2 1,056 35.6 494 (321) 15.6 (14.1)
Surgical site 2,908 14.8 384 12.9 876 (683) 27.7 (30.0)
Respiratory tract 1,041 5.3 614 20.7 604 (397) 19.1 (17.4)
Bloodstream 2,230 11.4 415 14.0 357 (258) 11.3 (11.3)
Other 3,390 17.3 497 16.8 836 (619) 26.4 (27.2)
Source of infection
Community 10,658 55.7 1,169 40.5 1,105 (781) 35.6 (34.9)
Nosocomial 7,606 39.8 1,592 55.2 1,771 (1,284) 57.1 (57.4)
Nosocomial other admissionb 870 4.5 123 4.3 224 (172) 7.2 (7.7)
Hospital size 
(number of beds)
<200 5,568 28.1 688 23.0 697 (482) 21.8 (20.9)
200–500 8,030 406 1,256 41.9 1,297 (952) 40.5 (41.3)
>500 6,198 31.3 1,053 35.1 1,210 (873) 37.8 (37.8)
Ward
Medical 8,950 45.5 1,352 45.3 914 (643) 28.8 (28.1)
Surgical 6,314 32.1 867 29.1 1,422 (1, 062) 44.7 (46.4)
Intensive care unit 1,462 7.4 415 13.9 526 (352) 16.5 (15.4)
Gynecology and obstetrics 635 3.2 47 1.6 48 (30) 1.5 (1.3)
Pediatric 1,623 8.3 206 6.9 210 (163) 6.6 (7.1)
Other 680 3.5 95 3.2 59 (38) 1.9 (1.7)
a Numbers in parentheses are specific for Enterobacter cloacae.
b Patients hospitalised who, at the time of the survey, presented a nosocomial infection acquired during a previous admission in the same or 
another hospital.
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significantly associated to nosocomial infections, and 
the rates of fluoroquinolone resistance increased with 
the size of the hospital, or age of the patients, espe-
cially in patients older than one year. For the type of 
ward, a high rate of resistance was found in patients 
admitted to ICU (23.1%), and the lowest rates of resist-
ance were found in paediatric (2.9%). For localisation 
of infection, UTI showed the highest rate of resistance 
(Table 2).
Enterobacter species infections
Nosocomial acquisition, ICU and pediatric wards, as 
well as bloodstream infections and UTI showed the 
highest prevalence of Enterobacter spp. resistance to 
Table 2
Prevalence of resistance to third-generation cephalosporins and fluoroquinolones by microorganism and by characteristics 
of patient, infection, and hospital, Spain, 1999–2010
 
 
 
Escherichia coli Klebsiella pneumoniae Enterobacter spp. (Enterobacter cloacae)a
Third-generation
cephalosporin 
resistance
Fluoroquinolone 
resistance
Third-generation
cephalosporin 
resistance
Fluoroquinolone 
resistance
Third-generation
cephalosporin resistance
Fluoroquinolone 
resistance
Rate 
(in %) p value
Rate 
(in %) p value
Rate 
(in %) p value
Rate 
(in %) p value
Rate 
(in %) p value
Rate 
(in %) p value
Sex
Male 10.2 0.016 27.7 <0.001 14.4 0.775 17.9 0.486 25.1 (26.8) 0.982 (.961) 10.3 (10.6) 0.116 (.314)
Female 9.2 24.7 14.0 16.9 25.1 (27.0) 8.5 (9.3)
Age (in years)
≤1 4.8 <0.001 5.8 <0.001 17.4 0.315 2.8 <0.001 29.8 (33.6) 0.274 (.206) 3.9 (5.1) 0.012 (.033)
1–15 7.1   6.7   5 10.0 18.8 (21.1)   4.2 (2.6)  
16–45 8.4   20.5   13.3 16.0 25.7 (28.9)   10.2 (10.6)  
46–65 9.8   25.6   13.8 17.7 23.1 (24.6)   8.4 (8.9)  
>65 10.5   30.1   14.4 19.3 25.5 (26.8)   10.8 (11.3)  
Localisation of infection
Urinary tract 8.7 <0.001 26.7 <0.001 16.6 0.065 22.7 <0.001 28.3 (32.4) 0.002 (.005) 13.2 (16.2) 0.015 (.001)
Surgical site 10.5   22.9   15.1   14.1 25.9 (26.1)   7.6 (7.8)
Respiratory tract 14.7   30.9   12.1   14.5   25.3 (28.7)   10.3 (10.1)
Bloodstream 9.7   25.1   12.5   14.0   29.1 (30.6)   8.1 (8.5)
Other 10.3   26.7   13.1   15.9   20.2 (22.1)   10.0 (10.5)
Source of infection
Community 7.9 <0.001 24.8 <0.001 8.6 <0.001 12.1 <0.001 20.8 (23.4) <0.001 (.002) 9.4 (10.8) 0.947 (.686)
Nosocomial 11.6   27.3   17.9   21.0   28.0 (29.8)   9.8 (9.7)  
Nosocomial other 
admissionb 14.7   32.2   20.3   18.7   23.2 (21.5)   9.8 (9.3)  
Hospital size (number of beds)
<200 8.5 <0.001 25.6 0.012 13.7 0.016 15.6 0.038 24.0 (26.6) 0.238 (.157) 8.6 (8.9) 0.007 (.010)
200–500 8.9   25.4   12.5   16.4   24.1 (25.0)   8.2 (8.4)  
>500 11.9   27.4   16.6   19.7   26.7 (29.0)   11.7 (12.5)  
Ward
Medical 10.4 <0.001 31.4 <0.001 13.5 0.036 19.1 <0.001 24.1 (26.1) 0.002 (.001) 12.4 (13.4) <0.001 (<.001)
Surgical 9.5   24.2   13.1   14.5 22.6 (22.8)   8.6 (8.5)  
Intensive care unit 13.3   27.0   18.3   23.1   31.6 (36.4)   10.3 (11.6)  
Gynecology and 
obstetrics 4.4   10.6   4.3   6.4   22.9 (23.3)   0.0 (0)  
Pediatric 5.5   5.4   16.0   2.9   28.6 (33.1)   2.9 (3.1)  
Other 7.2   32.6   16.8   30.5   30.5 (36.8)   16.9 (18.4)  
a Numbers in parentheses are for Enterobacter cloacae.
b Patients hospitalised who, at the time of the survey, presented a nosocomial infection acquired during a previous admission in the same or 
other hospital.
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third-generation cephalosporins. For fluoroquinolones 
resistance, the factors found associated were age, 
hospital size, ward type and localisation of infection 
(Table 2). 
Average of resistance for E. cloacae and E.  aerogenes 
did not differ significantly (26.9% vs 24.1%, RR:1.12, 
95% CI: 0.95–1.31, and 10.1% vs 9.4%, RR:1.08 95% 
CI:0.81–1.43, for resistance to third-generation cepha-
losporins and to fluoroquinolones respectively).
Regarding the main species of Enterobacter (E. cloacae) 
significant differences were found in rates of resist-
ance to third-generation cephalosporins, for localisa-
tion of infection (highest in UTI, 32.4%), nosocomial 
(29.8%) and type of ward (highest in ICU, 36.4%), and 
in rates of resistance to fluoroquinolones for increas-
ing age, size of the hospital, localisation of infection 
(highest in UTI, 16.2%), and type of ward (highest in 
medical ward patients, 13.4%) (Table 2). 
Trends in antimicrobial use and resistance
Antimicrobial use (number of patients receiving anti-
biotic/100 admitted patients) increased steadily for 
fluoroquinolones from 5.8% in 1999 to 10.2% in 2010 
(p<0.001), but no significant trend was observed for 
third-generation cephalosporins use (from 6.4% in 
1999 to 5.9% in 2010) (Figure 1). 
Proportion of resistance to third-generation cepha-
losporins increased significantly for E.  coli infections 
(from 4.6% to 15.4%, p<0.01) and for K.  pneumoniae 
infections (from 3.9% to 20.8%, p<0.01) with a more pro-
nounced increase since year 2004. Nevertheless third-
generation cephalosporins resistance for Enterobacter 
spp. did not show a trend, and ranged from 22.5% to 
31% with a mean rate of 24.3% (Figure 2). 
Proportion of resistance to fluoroquinolones increased 
significantly for E. coli infections (from 15.9% to 29.6%, 
p<0.01), and to a minor extent for Enterobacter spp. 
(from 6.4% to 14.9%, p<0.01). For K. pneumoniae there 
was a great increase (from 5.5% to 22.4%, p<0.01), also 
more pronounced since 2004 (Figure 3). 
Proportion of co-resistance to fluoroquinolones and 
third-generation cephalosporins increased signifi-
cantly for E. coli infections (from 1.6% to 11.3%, p<0.01), 
for Enterobacter spp. (from 4.8% to 9.5%, p<0.01), and 
to a higher extent for K.  pneumoniae infections (from 
0.8% to 14.4%, p<0.01) and more pronounced during 
the period from 2004 to 2007 (Figure 4).
We found strong correlations for rates of E. coli resist-
ant to fluoroquinolones, resistant to third-generation 
cephalosporins, or co-resistant to third-generation 
cephalosporins and fluoroquinolones, by the rate 
of use of fluoroquinolones (R=0.97, p<0.01; R=0.94, 
p<0.01; and R=0.96, p<0.01, respectively) (Figure 5A). 
Figure 2
Annual rates of Enterobacteriaceae resistant to third-
generation cephalosporins, Spain, 1999–2010
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Figure 3
Annual rates of Enterobacteriaceae resistant to 
fluoroquinolones, Spain, 1999–2010
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Figure 1
Annual use of fluoroquinolones and third-generation 
cephalosporins, Spain, 1999–2010
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Use of fluoroquinolones or third-generation cephalosporins is 
defined as the number of patients receiving either type of 
antimicrobial per 100 patients on the day of the annual survey.
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Also we found strong correlations for rates of K. pneu-
moniae resistant to fluoroquinolones, to third-genera-
tion cephalosporins, or co-resistant to third-generation 
cephalosporins and fluoroquinolones, by the rate 
of use of fluoroquinolones (R=0.92, p<0.01; R=0.91, 
p<0.01; and  R=0.92, p<0.01, respectively) (Figure 5B), 
but these correlations could not be found by the use 
of third-generation cephalosporins. No significant cor-
relations could be found for Enterobacter spp. resistant 
to third-generation cephalosporins and use of third-
generation cephalosporins or of fluoroquinolones. This 
was also the case for Enterobacter spp. resistant to 
fluoroquinolones and use of third-generation cepha-
losporins or fluoroquinolones.
Discussion
In the present study, we observed an increase in rates 
of resistance to third-generation cephalosporins and 
fluoroquinolones in the past twelve years in the main 
Enterobacteriaceae causing infections in hospitalised 
patients in Spain. This high rate of antibiotic resist-
ance could increase the risk of inappropriate empirical 
therapy in hospitalised patients with potentially seri-
ous infections. In Spain, fluoroquinolones and third-
generation cephalosporins can be used empirically for 
both nosocomial and community-acquired pneumonias 
and UTIs. The increase in resistance to fluoroquinolo-
nes and third-generation cephalosporins nevertheless 
differed among Enterobacteriaceae representatives. 
Enterobacter spp. (mainly E.  cloacae) displayed the 
highest rates of resistance to third-generation cepha-
losporins and the rates did not increase over time, but 
by 2010 E. coli and K. pneumoniae isolates were 3.3 and 
5.3 times more frequently resistant respectively than 
in 1999. The difference in resistance for Enterobacter 
spp. could be due to the fact that the main mecha-
nism of resistance to third-generation cephalosporins 
for Enterobacter spp. is overproduction of AmpC beta-
lactamases, whereas for E.  coli and K.  pneumoniae 
the main resistance mechanism is extended-spectrum 
beta-lactamases (ESBL) that has been related to anti-
biotic usage [9].
Overall, an increase in resistance to fluoroquinolones 
was observed for all three microorganisms reaching 
levels of resistance of 30%, 22%, and 15%, for E. coli, 
K pneumoniae, and Enterobacter spp. respectively. 
This tremendous increase in resistance was encom-
passed over the same time period by a 75% increase 
in the use fluoroquinolones in the hospitalised popu-
lation. Furthermore, strong correlations were found 
for the use of fluoroquinolones inside the hospital and 
resistance to fluoroquinolones, to third-generation 
cephalosporins, or co-resistance to both groups of 
the latter antimicrobials for E. coli and K. pneumoniae. 
From a microbiological point of view, the increase of 
Figure 4
Annual rates of Enterobacteriaceae co-resistant to 
fluoroquinolones and third-generation cephalosporins, 
Spain, 1999–2010
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Correlation between annual rate of fluoroquinolone use 
and resistance to fluoroquinolones, third-generation 
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resistance to fluoroquinolones has been associated 
with mutations in the topoisomerases [10] and more 
recently by the acquisition of plasmid mediated fluo-
roquinolones resistance genes such as qnr, aac(6`)-I-
cr or qep particularly in ESBL producing isolates [11]. 
Although the use of third-generation cephalosporins 
did not increase over the time period surveyed, use of 
this antimicrobial was maintained. The continuing use 
of third-generation cephalosporins could have contrib-
uted to an increase in the rate of resistance of E.  coli 
and K. pneumoniae to third-generation cephalosporins. 
In the hospital environment, the increase of fluoro-
quinolone use may also have allowed cephalosporin-
resistant Enterobacteriaceae to acquire additional 
resistance to fluoroquinolones. A co-selection process 
of co-resistance might have occurred [12].
In recent years, other studies have observed Spain as 
one of the countries in Europe with the highest use of 
fluoroquinolones outside the hospital [13]. This may 
have a role in co-selection and co-resistance, and 
potential clonal expansion influencing the results of 
this study. The observed differences in third-generation 
cephalosporin resistance among Enterobacteriaceae 
representatives could be related to the main resistance 
mechanism in the different studied bacteria (ESBL in 
E. coli and K. pneumonaie or AmpC hyperproduction in 
Enterobacter spp.) [14]. 
Not surprisingly, rates of resistance to third-generation 
cephalosporins were higher for ICU infected patients 
than on average, but the highest rates of fluoroqui-
nolone resistance were found outside the ICUs (Table 
2) probably related to the widespread use of this class 
of antimicrobial outside the ICUs.
It is important to note that resistance to antimicrobi-
als can differ depending of the site of the infection. For 
E.  coli the main resistance to third-generation cepha-
losporins was found in respiratory tract infections 
(14.7%), infections that are rarely caused by E.  coli 
outside the critical care units [15], a much higher rate 
than that for bloodstream infections (9.7%, p<0.001). 
Nevertheless, for Enterobacter spp. the highest rates 
of third-generation cephalosporin resistance were 
found for bloodstream infections (29.1%). Regarding 
resistance to fluoroquinolones the highest resistance 
in E. coli was for respiratory tract infections, while for 
K. pneumoniae and Enterobacter spp. was for UTI. It is 
important to keep in mind these differences when com-
paring to rates derived from a single site of infection.
It is also of note that for all these enterobacterial infec-
tions more than 50% (56% for E. coli and 41% and 36% 
for K. pneumoniae and Enterobacter spp., respectively) 
are community-acquired infections, that 88% of them 
are not bloodstream infections, and that looking for 
resistance only in nosocomial or bloodstream infec-
tions, in studies of antimicrobial resistance, can omit 
an important and valuable information for the develop-
ment of prevention strategies.
Regarding co-resistance to both fluoroquinolones and 
third-generation cephalosporins, Enterobacter spp., 
E. coli and K. pneumoniae increased significantly their 
rates of co-resistance with time, but the most pro-
nounced increase could be observed for K.  pneumo-
niae reaching rates of co-resistance of almost 15% in 
the 2007–2010 period. It has been reported that many 
enterobacteria strains resistant to third-generation 
cephalosporins are also resistant to fluoroquinolone, 
and that this co-resistance could be mediated by plas-
mids harbouring both quinolone resistance and ESBL 
genes or presence of different plasmids harbouring 
these resistance genes [16]. It is remarkable that the 
greatest increase in co-resistance for these microor-
ganisms, and to some extent for the resistance to fluo-
roquinolones and to third-generation cephalosporins, 
started around year 2004. These facts do not seem to 
be related to the antimicrobial use of fluoroquinolones 
or third-generation cephalosporins in hospitals, nei-
ther to any other fact known by us, and remains to be 
elucidated. It should be interesting to study the rela-
tionship of these facts with the consumption of other 
antimicrobial, such as amoxicillin-clavulanic, broadly 
used in Spain, since new formulations, for oral and 
parenteral routes, with increased dosage started to be 
marketed in Spain at the end of 2003.
To which extent rates of resistance derived from point 
prevalence studies can be overestimated when these 
rates of resistance are derived from an augmented 
length of infectious state attributable to antimicrobial 
resistance, needs further evaluation. When comparing 
data from our study to those reported by the European 
Antimicrobial Resistance Surveillance Network (EARS-
net, formerly EARSS) for the period 2007–2009 in 
Spain, only slight differences were found (values for 
EARS-net and EPINE: non-suceptible E.  coli to fluo-
roquinolones 32.3% vs 28.7%, or to third-genera-
tion cephalosporins 9.5% vs 10.7%, non-susceptible 
K.  pneumoniae: to fluoroquinolones 17.2% vs 20.8%, 
to third-generation cephalosporins 11.1% vs 16.0%) 
[17]. Nevertheless, it should be taken into account that 
EARS-net records data to a net of national surveillance 
systems only on invasive infections, from voluntary 
clinical laboratories in Spain (between 29 to 33 and 
between 14 to 33 laboratories reporting for E. coli and 
K.  pneumoniae, respectively), as opposed to the data 
from around 265 hospitals per year in EPINE, and that 
huge variations are found among laboratories reflect-
ing wide local variations in rates of resistance [18].
There are some limitations for our study. As hospi-
tals participated on a voluntary or compulsory basis, 
but were not selected at random, representativeness 
applies to regions where the study is mandatory but 
can not be warranted at the national level. On the other 
hand, this prevalence series represents more than half 
of the population hospitalised in acute care centres in 
Spain on a given day, and most data come from hos-
pitals that have regularly participated in the survey 
every year so concerns about representativeness are 
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diminished. Another limitation of our work is related 
to the non-experimental nature of the study so that to 
which extent this increase in antimicrobial resistance 
can be attributable to the increase in the use of fluo-
roquinolones cannot be concluded from the results 
of this ecological study but those results points out 
to this direction. One of the concerns about general-
ising our data is seasonality. As the survey was per-
formed every year during May, seasonal variations in 
time could not be assessed. However, the fact that we 
performed the survey in the same season each year, 
although precluding a study of seasonality, allowed 
us to measure trends. Finally, point prevalence studies 
prove to be useful to monitor trends on rates of resist-
ance and antimicrobial use at a national level, and can 
provide valuable information for comparisons among 
European Union Member States. Furthermore the infor-
mation on antimicrobial use and resistance gathered 
by national prevalence surveys, linked to patient and 
infection characteristics, not focused exclusively on 
invasive infections, can complement that of much rigor-
ous databases, from the microbiological point of view, 
such as EARS-net and could help to develop national 
strategies to prevention.
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